Regeneron Expands Irish Bioprocessing Campus

Article

Regeneron announced additional investments to its Limerick, Ireland biologics production facility.

Regeneron Pharmaceuticals is investing an additional $350 million in its Limerick Industrial Operations and Product Supply (IOPS) bioprocessing campus and will add another 200 jobs, bringing the total expected job creation in the Limerick, Ireland area to 500 jobs and total investment to $650 million by the end of 2017, the company announced on Oct. 19, 2015.

The US-based company acquired the former Dell Computer facility in Limerick and achieved planning approval in April 2014 for its first IOPS site outside of the United States. When the investment was initially announced in December 2013, a $300-million investment with 300 jobs was planned for delivery by the end of 2016. With this expansion of scope, the Limerick IOPS campus will house the largest-scale bulk biologics production facility in Ireland.

Regeneron's 400,000-ft2 biologics production facility in Limerick is now operational, with the first production line on track to enter validation before year-end 2015. Regeneron has worked closely with the Department of Jobs and IDA Ireland on the development of its operations in Ireland. In addition to the IOPS operations in Limerick, Regeneron also has a growing multi-functional team in Dublin supporting its business in Europe. Regeneron's total headcount in Ireland is expected to approach 550 by the end of 2017.

Source: Regeneron

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content